Efavirenz: a review

Bibliography

• Sustiva® (efavirenz), package insert. Bristol-Myers Squibb, NJ, USA (2004)
   Google Scholar
• YENI PG, HAMMER SM, HIRSCH MS et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 292(2):251-265.
   PubMed Web of Science ®Google Scholar
• VAN LETH F, PHANUPHAK P, STROES E et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. (2004) 1(1):e19.
   PubMed Web of Science ®Google Scholar
• YOUNG SD, BRITCHER SF, TRAN LO et al.: L-743, 726(DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1995) 39(12):2602-2605.
   PubMed Web of Science ®Google Scholar
• PAUWELS R: New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol. (2004) 4(5):437-446.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, DEJESUS E, ARRIBAS JR et al.: Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. (2006) 354(3):251-260.
   PubMed Web of Science ®Google Scholar
• MANNHEIMER S, FRIEDLAND G, MATTS J, CHILD C, CHESNEY M: The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin. Infect. Dis. (2002) 34(8):1115-1121.
   PubMed Web of Science ®Google Scholar
• SPENCE RA, KATI WM, ANDERSON KS, JOHNSON KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (1995) 267(5200):988-993.
   PubMed Web of Science ®Google Scholar
• DEEKS SG: International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. (2001) 26 (Suppl. 1):S25-S33.
   PubMed Web of Science ®Google Scholar
• BACHELER LT, ANTON ED, KUDISH P et al.: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. (2000) 44(9):2475-2484.
   PubMed Web of Science ®Google Scholar
• JOLY V, DESCAMPS D, PEYTAVIN G et al.: Evolution of human immunodeficiency virus type 1(HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob. Agents Chemother. (2004) 48(1):172-175.
   PubMed Web of Science ®Google Scholar
• OETTE M, KAISER R, DAUMER M et al.: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J. Acquir. Immune Defic. Syndr. (2006) 41(5):573-581.
   PubMed Web of Science ®Google Scholar
• WHITCOMB JM, HUANG W, LIMOLI K et al.: Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. Aids (2002) 16(15):F41-F47.
   PubMed Web of Science ®Google Scholar
• HAUBRICH RH, KEMPER CA, HELLMANN NS et al.: The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. Aids (2002) 16(15):F33-F40.
   PubMed Web of Science ®Google Scholar
• TOZZI V, ZACCARELLI M, NARCISO P et al.: Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J. Infect. Dis. (2004) 189(9):1688-1695.
   PubMed Web of Science ®Google Scholar
• SHULMAN NS, BOSCH RJ, MELLORS JW, ALBRECHT MA, KATZENSTEIN DA: Genetic correlates of efavirenz hypersusceptibility. Aids (2004) 18(13):1781-1785.
   PubMed Web of Science ®Google Scholar
• CLARK SA, SHULMAN NS, BOSCH RJ, MELLORS JW: Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. Aids (2006) 20(7):981-984.
   PubMed Web of Science ®Google Scholar
• VINGERHOETS J, AZIJN H, FRANSEN E et al.: TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. (2005) 79(20):12773-12782.
   PubMed Web of Science ®Google Scholar
• SANKATSING SU, WEVERLING GJ, PEETERS M et al.: TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. Aids (2003) 17(18):2623-2627.
   PubMed Web of Science ®Google Scholar
• GOEBEL F, YAKOVLEV A, POZNIAK A et al.: TMC278: potent anti-HIV activity in antiretroviral therapy-naive patients. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (22 – 25 February 2005) 160.
   Google Scholar
• HERNANDEZ J, AMADOR L, AMANTEA M et al.: Short-course monotherapy with AG1549, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI), in antiretroviral naive patients. Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (30 January – 2 February 2000) 169.
   Google Scholar
• PESANO R, PIRAINO S, HAWLEY P et al.: 24 week safety, tolerability, and efficacy of capravirine as add-on therapy to nelfinavir and 2 nucleoside reverse transcriptase inhibitors in patients failing a non-nucleoside reverse transcriptase inhibitor-based regimen. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (22 – 25 February 2005) 555.
   Google Scholar
• ROMINES K, ST.CLAIR M, HAZEN R et al.: Antiviral characterization of GW8248, a novel benzophenone non-nucleoside reverse transcriptase inhibitor. Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (13 – 16 July 2003) 535.
   Google Scholar
• BONNEAU P, ROBINSON P, DUAN J et al.: Antiviral characterization and human experience with BILR 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor with a broad anti HIV-1 profile. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (22-25 February 2005) 558.
   Google Scholar
• COULOMBE R, FINK D, LANDRY S et al.: Crystallographic study with BILR 355 BS, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (24 – 27 July 2005) WePp0105.
   Google Scholar
• REDDY YS, GOTZKOWSKY SK, ERON JJ et al.: Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J. Infect. Dis. (2002) 186(9):1339-1343.
   PubMed Web of Science ®Google Scholar
• GHOSN J, CHAIX ML, PEYTAVIN G et al.: Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. Aids (2004) 18(14):1958-1961.
   PubMed Web of Science ®Google Scholar
• ADKINS JC, NOBLE S: Efavirenz. Drugs (1998) 56(6):1055-1064; discussion 1065-1056.
   PubMed Web of Science ®Google Scholar
• DIETERICH DT, ROBINSON PA, LOVE J, STERN JO: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. (2004) 38 (Suppl. 2):S80-S89.
   PubMed Web of Science ®Google Scholar
• FELLAY J, MARZOLINI C, DECOSTERD L et al.: Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur. J. Clin. Pharmacol. (2005) 60(12):865-873.
   PubMed Web of Science ®Google Scholar
• MANOSUTHI W, KIERTIBURANAKUL S, SUNGKANUPARPH S et al.: Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. Aids (2006) 20(1):131-132.
   PubMed Web of Science ®Google Scholar
• WEINER M, BENATOR D, PELOQUIN CA et al.: Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin. Infect. Dis. (2005) 41(9):1343-1349.
   PubMed Web of Science ®Google Scholar
• GERBER JG, ROSENKRANZ SL, FICHTENBAUM CJ et al.: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. (2005) 39(3):307-312.
   PubMed Web of Science ®Google Scholar
• CSAJKA C, MARZOLINI C, FATTINGER K et al.: Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. (2003) 73(1):20-30.
   PubMed Web of Science ®Google Scholar
• PFISTER M, LABBE L, HAMMER SM et al.: Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. (2003) 47(1):130-137.
   PubMed Web of Science ®Google Scholar
• KAPPELHOFF BS, VAN LETH F, MACGREGOR TR et al.: Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir. Ther. (2005) 10(1):145-155.
   PubMed Web of Science ®Google Scholar
• BURGER D, VAN DER HEIDEN I, LA PORTE C et al.: Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol. (2006) 61(2):148-154.
   PubMed Web of Science ®Google Scholar
• MARZOLINI C, TELENTI A, DECOSTERD LA et al.: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids (2001) 15(1):71-75.
   PubMed Web of Science ®Google Scholar
• HAAS DW, RIBAUDO HJ, KIM RB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids (2004) 18(18):2391-2400.
   PubMed Web of Science ®Google Scholar
• HASSE B, GUNTHARD HF, BLEIBER G, KRAUSE M: Efavirenz intoxication due to slow hepatic metabolism. Clin. Infect. Dis. (2005) 40(3):e22-e23.
   PubMed Web of Science ®Google Scholar
• ROTGER M, COLOMBO S, FURRER H et al.: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics (2005) 15(1):1-5.
   PubMedGoogle Scholar
• NETTLES RE, KIEFFER TL, PARSONS T et al.: Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin. Infect. Dis. (2006) 42(8):1189-1196.
   PubMed Web of Science ®Google Scholar
• LETH FV, KAPPELHOFF BS, JOHNSON D et al.: Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res. Hum. Retroviruses (2006) 22(3):232-239.
   PubMed Web of Science ®Google Scholar
• KAPPELHOFF BS, CROMMENTUYN KM, DE MAAT MM et al.: Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. (2004) 43(13):845-853.
   PubMed Web of Science ®Google Scholar
• NUNEZ M, GONZALEZ DE REQUENA D, GALLEGO L et al.: Higher efavirenz plasma levels correlate with development of insomnia. J. Acquir. Immune Defic. Syndr. (2001) 28(4):399-400.
   PubMed Web of Science ®Google Scholar
• TAYLOR S, ALLEN S, FIDLER S: Stop Study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (8 – 11 February 2004) 131.
   Google Scholar
• RIBAUDO HJ, HAAS DW, TIERNEY C et al.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. (2006) 42(3):401-407.
   PubMed Web of Science ®Google Scholar
• WATERS L, STEBBING J, JONES R et al.: A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J. Antimicrob. Chemother. (2004) 54(2):503-507.
   PubMed Web of Science ®Google Scholar
• VAN LETH F, ANDREWS S, GRINSZTEJN B et al.: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Aids (2005) 19(5):463-471.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. (1999) 341(25):1865-1873.
   PubMed Web of Science ®Google Scholar
• ALBRECHT MA, BOSCH RJ, HAMMER SM et al.: Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N. Engl. J. Med. (2001) 345(6):398-407.
   PubMed Web of Science ®Google Scholar
• ROBBINS GK, DE GRUTTOLA V, SHAFER RW et al.: Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. (2003) 349(24):2293-2303.
   PubMed Web of Science ®Google Scholar
• SHAFER RW, SMEATON LM, ROBBINS GK et al.: Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. (2003) 349(24):2304-2315.
   PubMed Web of Science ®Google Scholar
• SQUIRES K, LAZZARIN A, GATELL JM et al.: Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. (2004) 36(5):1011-1019.
   PubMed Web of Science ®Google Scholar
• MANFREDI R, CALZA L, CHIODO F: First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. Aids (2004) 18(17):2331-2333.
   PubMed Web of Science ®Google Scholar
• VAN LEEUWEN R, KATLAMA C, MURPHY RL et al.: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. Aids (2003) 17(7):987-999.
   PubMed Web of Science ®Google Scholar
• VAN LETH F, WIT FW, REISS P et al.: Differential CD4 T cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. HIV Med. (2004) 5(2):74-81.
   PubMed Web of Science ®Google Scholar
• RIDDLER SA, HAUBRICH R, DIRIENZO G et al.: A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142. Program and abstracts of the 16th International AIDS Conference. Toronto, Canada (13 – 18 August 2006) THLB0204.
   Google Scholar
• COZZI-LEPRI A, PHILLIPS AN, D’ARMINIO MONFORTE A et al.: Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogs in the Italian Cohort Naive Antiretrovirals (I.Co.NA) study. J. Infect. Dis. (2002) 185(8):1062-1069.
   PubMed Web of Science ®Google Scholar
• MATTHEWS GV, SABIN CA, MANDALIA S et al.: Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. Aids (2002) 16(1):53-61.
   PubMed Web of Science ®Google Scholar
• KEISER P, NASSAR N, WHITE C, KOEN G, MORENO S: Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin. Trials (2002) 3(4):296-303.
   PubMedGoogle Scholar
• MANOSUTHI W, SUNGKANUPARPH S, VIBHAGOOL A, RATTANASIRI S, THAKKINSTIAN A: Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med. (2004) 5(2):105-109.
   PubMed Web of Science ®Google Scholar
• MANFREDI R, CALZA L, CHIODO F: Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J. Acquir. Immune Defic. Syndr. (2004) 35(5):492-502.
   PubMed Web of Science ®Google Scholar
• NUNEZ M, SORIANO V, MARTIN-CARBONERO L et al.: SENC (Spanish efavirenz vs nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin. Trials (2002) 3(3):186-194.
   PubMedGoogle Scholar
• VAN LETH F, PHANUPHAK P, RUXRUNGTHAM K et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet (2004) 63(9417):1253-1263.
   Google Scholar
• GULICK RM, RIBAUDO HJ, SHIKUMA CM et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. (2004) 350(18):1850-1861.
   PubMed Web of Science ®Google Scholar
• CUZIN L, PUGLIESE P, BUGNON F et al.: Triple nucleoside reverse transcriptase inhibitor- vs nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. HIV Med. (2005) 6(6):388-395.
   PubMed Web of Science ®Google Scholar
• PEREZ-ELIAS MJ, MORENO A, MORENO S et al.: Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV Clin. Trials (2005) 6(6):312-319.
   PubMed Web of Science ®Google Scholar
• BARTLETT JA, JOHNSON J, HERRERA G et al.: Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J. Acquir. Immune Defic. Syndr. (2006) 43(3):284-292.
   PubMed Web of Science ®Google Scholar
• ARRIBAS JR, PULIDO F, MIRO JM et al.: High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). Aids (2002) 16(11):1554-1556.
   PubMed Web of Science ®Google Scholar
• PULIDO F, ARRIBAS JR, MIRO JM et al.: Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J. Acquir. Immune Defic. Syndr. (2004) 35(4):343-350.
   PubMed Web of Science ®Google Scholar
• ORKIN C, STEBBING J, NELSON M et al.: A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J. Antimicrob. Chemother. (2005) 55(2):246-251.
   PubMed Web of Science ®Google Scholar
• GULICK RM, RIBAUDO HJ, SHIKUMA CM et al.: Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 296(7):769-781.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, GARCIA-VIEJO MA, BLANCO JL et al.: Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin. Infect. Dis. (2000) 31(5):1266-1273.
   PubMed Web of Science ®Google Scholar
• BECKER S, RACHLIS A , GILL J et al.: Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads – a prospective, randomized, multicenter, open-label study (DMP 049). Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (4 – 8 February 2001) 20.
   Google Scholar
• MARTINEZ E, ARNAIZ JA, PODZAMCZER D et al.: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med. (2003) 349(11):1036-1046.
   PubMed Web of Science ®Google Scholar
• FISAC C, FUMERO E, CRESPO M et al.: Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. Aids (2005) 19(9):917-925.
   PubMed Web of Science ®Google Scholar
• BUCHER HC, KOFLER A, NUESCH R et al.: Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. Aids (2003) 17(17):2451-2459.
   PubMed Web of Science ®Google Scholar
• CALZA L, MANFREDI R, COLANGELI V et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. Aids (2005) 19(10):1051-1058.
   PubMed Web of Science ®Google Scholar
• MOLINA JM, JOURNOT V, MORAND-JOUBERT L et al.: Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J. Infect. Dis. (2005) 191(6):830-839.
   PubMed Web of Science ®Google Scholar
• ALLAVENA C, FERRE V, BRUNET-FRANCOIS C et al.: Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2005) 39(3):300-306.
   PubMed Web of Science ®Google Scholar
• FISCHL M, BASSETT R, COLLIER A et al.: Randomized, controlled trial of lopinavir/ritonavir + efavirenz vs efavirenz + 2 nucleoside reverse transcriptase inhibitors following a first suppressive 3- or 4-drug regimen in advanced HIV disease. 12th CROI. Boston, USA (22 – 25 February 2005) 162.
   Google Scholar
• WARD D, BUSH L, THIRY A et al.: Atazanavir/ritonavir (ATV/r) and efavirenz (EFV) NRTI-sparing regimens in treatment-naive adults: BMS-121 Study. Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27 – 30 September 2006) H-1057.
   Google Scholar
• BOYD MA, SIANGPHOE U, RUXRUNGTHAM K et al.: Indinavir/ritonavir 800/100 mg b.i.d. and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med. (2005) 6(6):410-420.
   PubMed Web of Science ®Google Scholar
• CARR A, COOPER DA: Adverse effects of antiretroviral therapy. Lancet (2000) 356(9239):1423-1430.
   PubMed Web of Science ®Google Scholar
• FELLAY J, BOUBAKER K, LEDERGERBER B et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 358(9290):1322-1327.
   PubMed Web of Science ®Google Scholar
• CLIFFORD DB, EVANS S, YANG Y et al.: Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. (2005) 143(10):714-721.
   PubMed Web of Science ®Google Scholar
• LOCHET P, PEYRIERE H, LOTTHE A et al.: Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. (2003) 4(1):62-66.
   PubMedGoogle Scholar
• FUMAZ CR, MUNOZ-MORENO JA, MOLTO J et al.: Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J. Acquir. Immune Defic. Syndr. (2005) 38(5):560-565.
   PubMed Web of Science ®Google Scholar
• GALLEGO L, BARREIRO P, DEL RIO R et al.: Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin. Infect. Dis. (2004) 38(3):430-432.
   PubMed Web of Science ®Google Scholar
• BICKEL M, STEPHAN C, ROTTMANNC et al.: Severe CNS side effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand. J. Infect. Dis. (2005) 37(6-7):520-522.
   PubMed Web of Science ®Google Scholar
• JOURNOT V, CHENE G, DE CASTRO N et al.: Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin. Infect. Dis. (2006) 42(12):1790-1799.
   PubMed Web of Science ®Google Scholar
• SULKOWSKI MS, THOMAS DL, MEHTA SH, CHAISSON RE, MOORE RD: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 35(1):182-189.
   PubMed Web of Science ®Google Scholar
• MANFREDI R, CALZA L, CHIODO F: Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. HIV Clin. Trials (2005) 6(6):302-311.
   PubMed Web of Science ®Google Scholar
• FRIIS-MOLLER N, KIRK O, REISS P et al.: Safety of non-nucleoside reverse transcriptase therapy: data from the EUROSIDA study (abstract 24). Abstracts of the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (Paris). Antivir. Ther. (2003) 8:L20.
   Google Scholar
• KAPPELHOFF BS, VAN LETH F, ROBINSON PA et al.: Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir. Ther. (2005) 10(4):489-498.
   PubMed Web of Science ®Google Scholar
• NEGREDO E, CRUZ L, PAREDES R et al.: Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin. Infect. Dis. (2002) 34(4):504-510.
   PubMed Web of Science ®Google Scholar
• FONTAS E, VAN LETH F, SABIN CA et al.: Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J. Infect. Dis. (2004) 189(6):1056-1074.
   PubMed Web of Science ®Google Scholar
• MANFREDI R, CALZA L, CHIODO F: An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J. Acquir. Immune Defic. Syndr. (2005) 38(2):236-238.
   PubMed Web of Science ®Google Scholar
• FUMAZ CR, TULDRA A, FERRER MJ et al.: Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J. Acquir. Immune Defic. Syndr. (2002) 29(3):244-253.
   PubMed Web of Science ®Google Scholar
• VAN LETH F, CONWAY B, LAPLUME H et al.: Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antivir. Ther. (2004) 9(5):721-728.
   PubMed Web of Science ®Google Scholar
• MURPHY R, MCMILLAN F, HICKS C et al..: Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral-naive subjects. 10th European AIDS Conference (EACS) (17 – 20 November 2005) Dublin, Ireland PE7.9/3.
   Google Scholar